.Net, Applications, Licensing and Pharmaceuticals

Seattle-based Icosavax, which is developing COVID-19 vaccines, files for IPO 4 years after launch

GeekWire

JULY 7, 2021

Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design. Icosavax filed a clinical trial application in Belgium in June for its RSV candidate and plans to initiate trials later this year, according to a company filing with the U.S. Net losses were $5.3

Development

Development Biotechnology Pharmaceuticals .Net

Mark Cuban on America’s future

The Verge

NOVEMBER 10, 2020

It’s like Fox News does its damage, and Facebook does even worse damage because it gets reinforced by people you actually know that are in your physical, your life bubble, in addition to just being on some wide social media net that you really don’t know the people and they’re abstract. Facebook’s not abstract, and that’s the huge difference.

Network

Network Google Social Sports

Information Technology Zone

Seattle-based Icosavax, which is developing COVID-19 vaccines, files for IPO 4 years after launch

Mark Cuban on America’s future

Webinars

Stay Connected